Lecture on Cell Signalling Through Cell Surface Receptors

0.0(0)
studied byStudied by 4 people
0.0(0)
full-widthCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/19

flashcard set

Earn XP

Description and Tags

These flashcards cover key concepts related to cell surface receptors, G-proteins, and the Ras signalling pathway in cell signalling.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

20 Terms

1
New cards

What is the function of adenylyl cyclase and phospholipase C in G-protein signalling?

They are activated by trimeric G-proteins to produce second messengers.

2
New cards

What are the second messengers produced by adenylyl cyclase and phospholipase C?

  • Adenylate cyclase - Cyclic AMP (cAMP)

  • Phospholipase C - inositol 1,4,5-triphosphate (IP3), and diacylglycerol (DAG).

3
New cards

How does phospholipase c work?

  • Cleaves phosphoinositol 4,5-biphosphate (PIP2) to produce IP3 and DAG

4
New cards

What do IP3 and DAG do?

IP3 - Release Ca2+ from the ER

DAG - Activates protein kinase C 

The Ca2+ and DAG released act together to activate Protein Kinase C

5
New cards

Why can Ca2+ be used as a second messenger?

  • Cytosolic Ca2+ levels (10-7) are usually lower compared to extracellular levels (10-3)

6
New cards

How does Ca2+ function as a secondary messenger

Ca2+ binds to proteins and induces conformational changes in those proteins.

7
New cards

What is calmodulin and its role in calcium signalling?

Calmodulin binds 4 Ca2+ ions and activates target proteins upon conformational change.

8
New cards

What are enzyme linked proteins?

  • Single span transmembrane proteins

  • Have cytosolic domains that either have intrinsic enzymatic activity, or are associated with an enzyme

9
New cards

What characterizes receptor tyrosine kinases (RTKs)?

They are a common type of enzyme-linked receptors with intrinsic kinase activity.

10
New cards

How do RTKs have intrinsic kinase activity?

  • When the ligand binds to growth factor receptors, it causes them to cross link

  • Oligomerisation of the RTKs allows for cross phosphorylation (auto-phosphorylation)

11
New cards

What is Ras?

A small monomeric G protein that is the main signal transducer protein for growth factors such as fibroblast growth factor (FGF) and epidermal growth factor (EGF). Ras plays a key role in regulating cell proliferation and survival.

12
New cards

Difference between monomeric and trimeric proteins?

<p></p>
13
New cards

What is the Ras-MAPK pathway's role in cell signalling?

It transduces signals from growth factors leading to cell proliferation and differentiation.

14
New cards

How is the RAS-MAPK pathway activated?

1 - A growth factor (like EGF or insulin) binds to its receptor, activating it.
2 - The RTKs auto-phosphorylate and become docking sites for intracellular signal proteins

3 - Grb2 binds to the receptor, and Ras-GEF (SOS) binds to it, and is activated

4 - SoS then promotes the exchange of GDP for GTP, activating Ras.

The activated Ras triggers a downstream phosphorylation cascade

15
New cards

What is the pattern of the RAS phosphorylation cascade?

Raf (MAP kinase kinase kinase), MEK (MAP kinase kinase), and ERK(MAP kinase)

16
New cards

What does ERK phosphorylate?

  • Protein X and Y (that cause change in protein activity)

  • Transcription regulatory protein A and B (that cause changes in gene expression)

17
New cards

What types of cancers are associated with Ras mutations?

20-30% of human cancers, especially 80% of pancreatic cancers.

18
New cards

What role do GTPase-activating proteins (GAPs) play in Ras signalling?

GAPs help drive the hydrolysis of GTP to GDP, inactivating Ras.

19
New cards

What happens when there are mutations in the Ras gene?

Mutations can reduce GTP hydrolysis activity, leading to continuous cell proliferation.

20
New cards

What are some inhibitors targeting the Ras signalling pathway?

Examples include vemurafenib used in melanoma patients with specific mutations.